Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q8NER1

UPID:
TRPV1_HUMAN

ALTERNATIVE NAMES:
Capsaicin receptor; Osm-9-like TRP channel 1; Vanilloid receptor 1

ALTERNATIVE UPACC:
Q8NER1; A2RUA9; Q3LU47; Q9H0G9; Q9H303; Q9H304; Q9NQ74; Q9NY22

BACKGROUND:
The Transient receptor potential cation channel subfamily V member 1, known for its alternative names such as Capsaicin receptor and Vanilloid receptor 1, is integral in mediating responses to noxious heat and chemical stimuli. It is sensitized by various endogenous compounds, playing a key role in intracellular acidosis in nociceptive neurons, and is implicated in the modulation of inflammatory pain and hyperalgesia through its ionotropic endocannabinoid receptor function.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Transient receptor potential cation channel subfamily V member 1 offers a promising avenue for developing novel pain relief methods. Its capacity to be activated by both physical and chemical stimuli makes it a prime target for creating innovative treatments for chronic pain and inflammation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.